Atrium Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 257.1K | $3.44M | 0.00% | New | 2026-03-31 |
| TwoSigma | quant | 178.6K | $2.39M | 0.00% | New | 2026-03-31 |
| FidelityFMR | fundamental | 29.3K | $391.63K | 0.00% | New | 2026-03-31 |
| Citadel | multi-strat | 22.7K | $303.61K | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 1.55M | $20.77K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-14 | -1.05 | -0.97 | +7.62% |
| 2026-05-11 | -1.30 | — | — |
| 2026-02-23 | -1.26 | -1.59 | -26.37% |
| 2025-11-10 | -1.10 | -1.27 | -15.34% |
| 2025-08-07 | -0.96 | -1.21 | -26.33% |
| 2025-05-08 | -0.88 | -0.90 | -2.24% |
| 2025-02-27 | -0.78 | -0.80 | -2.45% |
| 2024-11-07 | -0.72 | -0.65 | +9.52% |
| 2024-08-09 | -0.78 | -0.65 | +17.12% |
| 2024-05-09 | -0.88 | -0.79 | +9.79% |
| 2024-02-28 | -0.63 | -0.79 | -25.00% |
| 2023-11-08 | -0.75 | -0.71 | +5.33% |
| 2023-08-08 | -0.79 | -0.66 | +16.81% |
| 2023-05-09 | -0.86 | -0.74 | +13.62% |
| 2023-02-28 | -0.88 | -0.88 | +0.38% |
| 2022-11-08 | -0.93 | -0.82 | +12.30% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| RNA | -3.20% | -21.40% | — | — |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | -6.17% | -16.58% | — | — |